Navigation Links
Sangamo BioSciences to Present at the 2007 BIO InvestorForum
Date:10/3/2007

RICHMOND, Calif., Oct. 3 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Philip Gregory, D.Phil., Sangamo's vice president of research, will provide an update on the progress of Sangamo's ZFP Therapeutic development programs and an overview of the company's business strategy at 12:45pm (PT) on Wednesday, October 10, 2007 at the BIO InvestorForum in San Francisco.

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section http://investor.sangamo.com/index.cfm under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy. Phase 1 clinical trials are ongoing to evaluate a ZFP Therapeutic for peripheral artery disease. Other therapeutic development programs are focused on cancer and HIV/AIDS, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specif
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Perscitus Biosciences secures $250K Commerce loan
2. Wisconsin biosciences rise to the challenge
3. Quintessence Biosciences advances cancer drug
4. Quintessence Biosciences names new president
5. Caden Biosciences may signal critical mass
6. Wisconsin start up Primorigen Biosciences corrals out-of-state investment
7. WARF signs licensing pact with BD Biosciences
8. Fisher Biosciences contracts with Madison-based GenTel BioSurfaces
9. State awards QRG Biosciences development grant
10. EMD Biosciences partners with European biotech company
11. Quintessence Biosciences forms cancer therapeutic advisory board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2008)...Newswire/ -- BioTrends Research Group, Inc.,releas...M) publication, a,syndicated report offering compr...ia and bone and mineral metabolism in Chronic Kidn... information from 182 US,Nephrologists -- data wer...ne 2008., In the renal anemia market, while the u...
(Date:7/25/2008)...X, CALGARY, July 25 / Resv...X:RVX) is pleased to announce effective,immediatel...irectors. On,the subject of her appointment Jan Gr...xciting opportunity for me. The Company has done a...linical trials. I expect the next,foreseeable futu...
(Date:7/25/2008)...swire-FirstCall/ -- Caraco Pharmaceutical,Laborato...first quarter of,Fiscal 2009, ended June 30, 2008,...or the corresponding period of Fiscal 2008. This r...er of Fiscal 2008. Pre-tax income grew,to $14.6 mi...ared to a,pre-tax income of $9.6 million during th...
(Date:7/25/2008)...25 /- REvolution Computing will,lead ...R product at the,upcoming BioC 2008 conference in ... REvolution Computing Director of Community, Dr. D... Training Manager, and Martin Morgan of,the Fred H...ting,s BioC lab,will introduce participants to the...
Breaking Biology Technology:BioTrends Releases Quarterly TreatmentTrends(TM): Nephrology Report Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism 2BioTrends Releases Quarterly TreatmentTrends(TM): Nephrology Report Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism 3Jan Gray Joins Resverlogix Board of Directors 2Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2009 2Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2009 3Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2009 4Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2009 5Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2009 6Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2009 7REvolution Computing Offers Hands-On Tutorial of NWS Parallel Computing Environment at BioC 2008 2
...ompanies have received a total of $195,500 in tax ...Doyle announced last Friday that Standard Imaging...ology Zone tax credits and Tushaus Computer Servi...e Technology Zone is a part of Doyles Grow Wiscons...s for high-tech growth in manufacturing, printing ...
... nothing is more important to a physician than the... and nurses alike are duty-bound to make sure that... as few errors as possible, pushing through layers...ghtest error from costing lives. , ,Keeping all th...d one which, according to Barry Chaiken MD, and Ja...
...sconsin and beyond have been given a new Web-based...mployees and interns among the graduates and stude...new Web site brings together the career services...nd provides links to the career services resources... the Wisconsin Technical College System and many o...
...n a roundtable discussion with HR executives in Lo...le for talent management and resourcing strategies...cussion was agile resourcing i.e., how to make th...goal of agile resourcing strategies is to make sur...h the right skills, in the right place, at the rig...
Other Biology Technology:Standard Imaging and Tushaus receive DOC Tech Zone credits 2Using clinical IT to improve care 2Using clinical IT to improve care 3New Web site makes recruiting from Wisconsin universities easier 2Stuck in Talent Gridlock 2Stuck in Talent Gridlock 3
(Date:7/25/2008)...ry specialists from 22 countries are sharing the l... such as mustard, radish, or rapeseed, to manage s...ofumigation. ," Brassica plants naturally relea...incipally isothiocyanates (ITCs), which most peopl...or horseradish," says CSIRO,s Dr John Kirkegaard. ...
(Date:7/24/2008)...by Massachusetts General Hospital (MGH) investigat...research and medicine a robust method for generat...NA sequences for inactivation or repair. In the ... describe an efficient, publicly available method ...), which can be used to induce specific genomic mo...
(Date:7/24/2008)...led cytomegalovirus (CMV), which most commonly aff...lso affect hospital intensive-care patients who ha...gton researchers have found. CMV infection is also...e unit (ICU) stays independent of other causes, ac... the Journal of the American Medical Association ...
(Date:7/24/2008)...the life of a cell, the response to DNA damage det...air itself, commit suicide, or grow uncontrollably...shed in the July 25th issue of Cell , scientists ...y that cells respond to DNA damage through a proce... points to a new pathway for the development of ca...
Breaking Biology News(10 mins):Consortium develops new method enabling routine targeted gene modification 2CMV infections affect more than just patients with compromised immune systems, researchers find 2A new cellular pathway linked to cancer is identified by NYU researchers 2CardioDynamics Provides 2007 Shareholder Meeting Update 31 1CardioDynamics Provides 2007 Shareholder Meeting Update 31 2CardioDynamics Provides 2007 Shareholder Meeting Update 31 3GlaxoSmithKline Recognizes University of Michigans Dr Daniel F Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award 28 1GlaxoSmithKline Recognizes University of Michigans Dr Daniel F Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award 28 2GlaxoSmithKline Recognizes University of Michigans Dr Daniel F Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award 28 3Benitec MOU With CalbaTech Inc 25 1Benitec MOU With CalbaTech Inc 25 2Benitec MOU With CalbaTech Inc 25 3Benitec MOU With CalbaTech Inc 25 4Boston Scientific to Explore Sale of Cardiac Surgery and Vascular Surgery Businesses 22 1Boston Scientific to Explore Sale of Cardiac Surgery and Vascular Surgery Businesses 22 2Boston Scientific to Explore Sale of Cardiac Surgery and Vascular Surgery Businesses 22 3
...nt form of good cholesterol provides significantly... than therapy using the "normal" HDL gene, accordi...chers at Cedars-Sinai Medical Center and reported ... College of Cardiology. , Apolipoprotein A-I is a...-density lipoprotein), the "good" cholesterol that...
...here there is a serious influenza outbreak will do...according to the findings of a study conducted at ...he journal PLoS Medicine. , Sometimes a new type ...hat is more serious than is usually the case for f...u pandemic killed between 20 million and 100 milli...
...f the human genome project, researchers at Dana-Fa... the Broad Institute of Harvard and MIT, and other...atic approach to drug discovery that matches disea...nguage based on cells, distinctive gene activity p...les being published in the September 29 issue of S...
...we hate. And yet, our "taste" for certain flavors ... we get tired of eating the same old thing. , Now...dence about what,s going on in the brain when we t...mething we once hated. , And although the study ...tions for understanding the way we perceive pleasu...
Other Biology News:Gene transfer using mutant form of good cholesterol cuts vascular plaque and inflammation 2Gene transfer using mutant form of good cholesterol cuts vascular plaque and inflammation 3Air travel and pandemic flu 2Scientists use gene signatures to match cancer and other diseases with potentially effective drugs 2Scientists use gene signatures to match cancer and other diseases with potentially effective drugs 3Tastes great! Study shows brain's response to pleasing -- and changing -- tastes 2Tastes great! Study shows brain's response to pleasing -- and changing -- tastes 3
Rabbit polyclonal to Wilms Tumor Protein ( Abpromise for all tested applications). entrezGeneID: 7490 SwissProtID: P19544
Ku80 Antibody Shipping Temperature: HOT Storage Temperature: -20C
Request Info
100 g monoclonal antibody which can immunocapture ~10 g of Complex IV from heart mitochondria. Also included are 2 mg of bovine heart mitochondria for control immunocapture.
Biology Products: